News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

DFFN: Phase 3 Trial of TSC in GBM to Initiate in 2017

Al's Comment:

 Results from earlier studies were impressive with " In the subgroup of patients considered inoperable, the chance of survival at two years for those who received TSC was increased by over 100 percent, as 40 percent in the TSC group were alive at two years compared to less than 20 percent in the control. "  

 


Posted on: 04/09/2017

DFFN: Phase 3 Trial of TSC in GBM to Initiate in 2017

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740